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Our best and alternative models are presented in Figures S3A-C , along with the AIC and position of knots. 2014  2012  2010  2008  2006  2004  2002  2000  1998  1996  1994  1992  1990  1988  1986  1984  1982  1980  1978  1976  1974  1972  1970  1968  1966  1964  1962  1960  1958  1956  1954  1952  1950  1948  1946  1944  1942  1940  1938  1936  1934  1932  1930  1928  1926  1924  1922  1920 The VE among the target group for vaccination is similar among the 0-14 age group compared to the general population (45% vs. 46%), but lower among 15-64 year olds (-5% vs. -26%). If clade 3C.3a strongly contributes to the low VE among 15-64 year olds, then the difference in VE in this age group among the target group for vaccination compared to the general population could be in part explained by the difference in distribution of 3C.3a vs. other clades. In the target group for vaccination, 24% of patients in the complete case analysis have viruses belonging to the 3C.3a clade.
In the general population, 32% of patients in the complete case analysis have viruses belonging to the 3C.3a clade. 
